Compare HASI & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HASI | PTGX |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.4B |
| IPO Year | 2012 | 2016 |
| Metric | HASI | PTGX |
|---|---|---|
| Price | $40.07 | $94.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $44.38 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 935.7K | 478.7K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $400,502,000.00 | N/A |
| Revenue This Year | $79.17 | $874.25 |
| Revenue Next Year | $207.88 | N/A |
| P/E Ratio | ★ N/A | $1,908.20 |
| Revenue Growth | ★ 4.41 | N/A |
| 52 Week Low | $24.40 | $49.86 |
| 52 Week High | $44.13 | $107.84 |
| Indicator | HASI | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 39.72 |
| Support Level | $39.74 | $90.58 |
| Resistance Level | $42.11 | $98.27 |
| Average True Range (ATR) | 0.93 | 3.75 |
| MACD | -0.17 | -0.90 |
| Stochastic Oscillator | 29.63 | 8.17 |
HA Sustainable Infrastructure Capital Inc is an investor in sustainable infrastructure assets advancing the energy transition. Its investment is focused on actively partnering with clients to deploy capital in income-generating real assets that are supported by long-term recurring cash flows. This enabled to the generation of attractive risk-adjusted returns and provided stockholders with diversified exposure to the energy transition. The company's single reportable segment generates net investment and equity method investment income through investments in energy transition assets and infrastructure projects, as well as revenue through the gain on sale of assets and recurring asset management fees.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.